Showing results (451-460 of 554) with videos related to

Sort By:
Pageof 56
JCO Precision Oncology|May 29, 2020
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsEmmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, et al.
American Journal of Human Genetics|August 16, 2006
Genomewide scan for nonsyndromic cleft lip and palate in multigenerational Indian families reveals significant evidence of linkage at 13q33.1-34Uppala Radhakrishna, Uppala Ratnamala, Mathew Gaines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.
Cancer Discovery|July 25, 2025
Off-pore nucleoporin sPOM121 transcriptionally propels β-Catenin driven tumor progression and immune escape in prostate cancerPerumalraja Kirthika, Vijayakumar Jawalagatti, Peiyao Li, et al.
Oncotarget|December 22, 2017
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomyAshley E Ross, Robert M Hughes, Stephanie Glavaris, et al.
Cancer Research Communications|January 28, 2025
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic TargetingJohn R Lozada, Andrew Elliott, Mark G Evans, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Arxiv|July 17, 2025
Circulating tumor cell detection in cancer patients using in-flow deep learning holographyKevin Mallery, Nathaniel R Bristow, Nicholas Heller, et al.
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
Nature Cancer|March 26, 2024
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancersMaishara Muquith, Magdalena Espinoza, Andrew Elliott, et al.
Pageof 56